2 ASX healthcare shares to buy that you've not heard of: expert

If you want to invest in a sector that people still need during economic downturns, here's a pair of small caps that might interest you.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare is one of those industries that enjoys relatively stable demand through tougher economic times.

With consecutive interest rises forcing Australians to close their wallets, this might be a consideration for the coming period.

But of course, the well-known ASX shares in the sector are already well bought.

So one Wilson Asset Management analyst has dug deeper into his research to come up with a couple of buys that are not yet household names:

'This company can re-rate over the next few years'

Probiotec Limited (ASX: PBP) only has a market capitalisation of $180 million. 

But for such a small cap it has managed to hold its stock price pretty well in 2022, only down 1.76% so far.

Wilson senior equity analyst Sam Koch is buying the pharmaceutical manufacturer and distributor.

"We believe the stock offers investors valuation and earnings upside," he said in a Wilson video.

"What the market's missing here is their ability to compound earnings growth at a very high rate, relative to its current valuation."

The business' "strong organic growth" is accompanied by bolt-on acquisitions, he added.

"Trading at 10 times P/E with over 15% [earnings per share] growth projected, we believe that this company can re-rate over the next few years."

While coverage is sparse on Probiotec, at least Shaw and Partners currently agrees with Koch, rating the stock as a strong buy.

Probiotec hands out a 2.5% dividend yield.

Share price now below PE ratio of ONE

CogState Limited (ASX: CGS) is arguably a technology business in addition to its involvement in the health sector.

That's because it's a cognitive science company that provides tech and services to biotechnology and pharmaceutical clients conducting clinical trials.

Koch said that big pharma relies on CogState's technology for their studies into Alzheimer's Disease.

"What we're really attracted to in CogState is that they were one of the first companies to provide the software-first technology, which has accelerated the industry's push towards decentralised clinical trials."

The value of CogState's services was recognised in one of its largest clients actually taking a 7% shareholding, according to Koch.

"The company's trading at below one times earnings-to-price growth multiple with over 15% of the market cap caught up in cash," he said.

"We believe that acquisitions and earnings upgrades will drive the stock from here."

According to CMC Markets, three of four analysts currently rate the stock as a strong buy.

The CogState share price has dropped more than 19% so far this year.

Should you invest $1,000 in The A2 Milk Company Limited right now?

Before you buy The A2 Milk Company Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and The A2 Milk Company Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited and Probiotec Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »